The leaps we're helping to deliver in research and innovation that inform better patient outcomes wouldn't be possible without our deep partnerships with researchers and clinicians across all sectors of the healthcare landscape — university, pharma, community health, and more.
The I-SPY series of trials are changing the way new treatments are developed — helping make available new, better and more personalized treatments, faster.
The ground-breaking I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer employs an 'adaptive' clinical trial model designed to increase trial efficiency by minimizing the number of participants and time required to evaluate an experimental agent.
.png)
I-SPY Phase 1b is an open-label platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients.
.png)
Identifying agents that can reduce mortality and the need for, as well as the duration of, mechanical ventilation or advanced respiratory support in patients with Acute Respiratory Distress Syndrome (ARDS).
Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer by evaluating three investigational endocrine therapy arms.
Download all the latest data and findings from our ongoing I-SPY 2 trials.
Interested in QLHC-related research? Find the links here.
A thorough collection of useful research and data resources.
Discover all the ways leading research organizations are...
Every contribution, no matter the size, helps us move closer to a future where healthcare is more precise, accessible, and tailored to every individual. Your support empowers innovation, fuels critical research, and strengthens our mission to advance personalized medicine that can improve lives across communities and generations.
